1 / 20

Eric Prystowsky, MD Director Clinical Electrophysiology Laboratory St Vincent Hospital

The EP show: Drug-induced torsades de pointes. Eric Prystowsky, MD Director Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Dan Roden, MD Director Division of Clinical Pharmacology, Vanderbilt University School of Medicine Nashville, TN.

zuzana
Download Presentation

Eric Prystowsky, MD Director Clinical Electrophysiology Laboratory St Vincent Hospital

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The EP show: Drug-induced torsades de pointes • Eric Prystowsky, MD • Director • Clinical Electrophysiology Laboratory • St Vincent Hospital • Indianapolis, IN • Dan Roden, MD • Director • Division of Clinical Pharmacology, • Vanderbilt University School of Medicine • Nashville, TN

  2. Torsades de pointes Scope of the problem • Incidence drug induced torsades is 1-5% in patients receiving QT-prolonging anti-arrhythmic drugs

  3. Torsades de pointes Withdrawals due to torsades

  4. Torsades de pointes Drug-drug interactions • In 1990’s life-threatening arrhythmias were discovered with Seldane. • It took millions of prescriptions to detect the problem - interaction with erythromycin and ketoconazole. • D Roden

  5. Torsades de pointes Too many drugs • The problem is there are so many drugs, and so many interactions, no one can keep track of it all. • We need to flag the major dangerous combinations, and a better understanding of mechanisms to predict future problems. • D Roden

  6. Torsades de pointes Computers to the rescue • “I think the savior in all this is going to be, and is, the internet and computerized prescribing programs, which won’t let you make prescriptions that will be life threatening.” • Dan Roden

  7. Torsades de pointes Repolarization reserve • How does the concept of “repolarization reserve” work, and how can we take advantage of it as clinicians? • Example: • In a patient who underwent a Holter monitor, the QT interval got alarmingly long at night time. No family history of problems • Is this a person we need to worry about giving a drug that prolongs the QT interval?

  8. Torsades de pointes Redundant systems • The heart has redundant systems to create repolarization • Reduced efficiency of one repolarizing mechanism might not cause a problem, but it makes the heart less able to cope with a drug that prolongs the QT-interval • Each hit to the system makes it more likely that a drug will be what pushes you over the edge to torsades • D Roden

  9. Torsades de pointes Patient possibilities • Something else going on in their life that is extending the QT-interval (i.e. intermittent LBBB, transient hypokalemia • Patient has congenital long-QT syndrome. (used to be 1 in 10,000 – but now we are much more sensitized to it) • Perhaps this is reduced repolarization reserve, and the patient is at higher risk when taking QT-interval prolonging drugs

  10. Torsades de pointes Clinical decision making • Should everyone get a Holter before getting QT-prolonging drugs? • A great theoretical idea, but simply not practical • No simple test to screen for susceptibility yet • The repolarization reserve concept lets us risk-stratify the patients, but we can’t measure the reserve directly • D Roden

  11. Torsades de pointes Clinical decision making • Mrs. Smith gets a potassium channel blocker and has long QT – does this rule out all QT-prolonging drugs? Or can you go after a different ionic channel? • We have other therapies, so why risk exposing them to another QT-prolonging drug? • The theory makes no distinction between the drug mechanisms that might provoke the long QT. • D Roden

  12. Torsades de pointes Amiodarone • There’s something very different about amiodarone. • The mechanism by which it prolongs the QT is not much different than other drugs, so it must have some other pharmacologic action that is potently anti-arrhythmic, even in the face of long QT. • The actual mechanism remains unclear. • D Roden

  13. Torsades de pointes Secondary proarrythmia • What is it that causes a patient to develop a late problem responding to QT-prolonging drugs? • Two possibilities for the late effect: • The drug is producing a greater effect: a change in concentration, hypokalemia accentuates the effect • something else has changed about their heart’s environment – ischemia, some more heart failure

  14. Torsades de pointes Something has changed • “It’s sort of self-evident that if somebody behaves in one way on July 1st and on August 1st they behave a different way then something has changed. Something has changed. And our job is to figure out what those things might be.” • Dan Roden

  15. Torsades de pointes Why late torsades appears • Most people who present with torsades after leaving the hospitalhave a fairly evident cause: • Recent bad heart failure • Severe hypokalemia • Bradycardia • Acquired heart block

  16. Torsades de pointes Appropriate follow up? • The incidence of torsades is not terribly high because we’ve become attuned to the problem • Must make sure the patient is well informed of situations with risk of torsades • Follow the patients with intermittent ECG • Don’t need to worry about it excessively • Dan Roden

  17. Torsades de pointes Inpatient initiation? • A vexing issue • Patients should be started on these drugs as inpatients • May not be highly cost-effective, but you need to reduce risks to the patients as much as possible • Dan Roden

  18. Torsades de pointes Do no harm • “In every patient, you just think of the worst thing that could happen and then say, ‘If I could live with that, then fine. If I can’t, then I better figure out a way of minimizing the chances that that will happen or find another drug, or another therapy.’” • Dan Roden

  19. Torsades de pointes Outpatient initiation • I am more willing to start certain patients I consider safe on an outpatient basis. • There probably is not a right or wrong answer, you have to go with a sense of your comfort level. • Eric Prystowsky

  20. Torsades de pointes Torsades de pointes

More Related